331 related articles for article (PubMed ID: 23776173)
1. Critical role of the tumor suppressor tuberous sclerosis complex 1 in dendritic cell activation of CD4 T cells by promoting MHC class II expression via IRF4 and CIITA.
Pan H; O'Brien TF; Wright G; Yang J; Shin J; Wright KL; Zhong XP
J Immunol; 2013 Jul; 191(2):699-707. PubMed ID: 23776173
[TBL] [Abstract][Full Text] [Related]
2. Role of PU.1 in MHC class II expression through transcriptional regulation of class II transactivator pI in dendritic cells.
Kitamura N; Yokoyama H; Yashiro T; Nakano N; Nishiyama M; Kanada S; Fukai T; Hara M; Ikeda S; Ogawa H; Okumura K; Nishiyama C
J Allergy Clin Immunol; 2012 Mar; 129(3):814-824.e6. PubMed ID: 22112519
[TBL] [Abstract][Full Text] [Related]
3. Positive regulatory domain I (PRDM1) and IRF8/PU.1 counter-regulate MHC class II transactivator (CIITA) expression during dendritic cell maturation.
Smith MA; Wright G; Wu J; Tailor P; Ozato K; Chen X; Wei S; Piskurich JF; Ting JP; Wright KL
J Biol Chem; 2011 Mar; 286(10):7893-7904. PubMed ID: 21216962
[TBL] [Abstract][Full Text] [Related]
4. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.
Soos JM; Krieger JI; Stüve O; King CL; Patarroyo JC; Aldape K; Wosik K; Slavin AJ; Nelson PA; Antel JP; Zamvil SS
Glia; 2001 Dec; 36(3):391-405. PubMed ID: 11746775
[TBL] [Abstract][Full Text] [Related]
5. Enhanced production of IL-10 by dendritic cells deficient in CIITA.
Yee CS; Yao Y; Xu Q; McCarthy B; Sun-Lin D; Tone M; Waldmann H; Chang CH
J Immunol; 2005 Feb; 174(3):1222-9. PubMed ID: 15661876
[TBL] [Abstract][Full Text] [Related]
6. CIITA promoter I CARD-deficient mice express functional MHC class II genes in myeloid and lymphoid compartments.
Zinzow-Kramer WM; Long AB; Youngblood BA; Rosenthal KM; Butler R; Mohammed AU; Skountzou I; Ahmed R; Evavold BD; Boss JM
Genes Immun; 2012 Jun; 13(4):299-310. PubMed ID: 22218223
[TBL] [Abstract][Full Text] [Related]
7. TSC1/mTOR-controlled metabolic-epigenetic cross talk underpins DC control of CD8+ T-cell homeostasis.
Shi L; Chen X; Zang A; Li T; Hu Y; Ma S; Lü M; Yin H; Wang H; Zhang X; Zhang B; Leng Q; Yang J; Xiao H
PLoS Biol; 2019 Aug; 17(8):e3000420. PubMed ID: 31433805
[TBL] [Abstract][Full Text] [Related]
8. MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity.
Benasciutti E; Mariani E; Oliva L; Scolari M; Perilli E; Barras E; Milan E; Orfanelli U; Fazzalari NL; Campana L; Capobianco A; Otten L; Particelli F; Acha-Orbea H; Baruffaldi F; Faccio R; Sitia R; Reith W; Cenci S
J Bone Miner Res; 2014 Feb; 29(2):290-303. PubMed ID: 24038328
[TBL] [Abstract][Full Text] [Related]
9.
Letendre C; Auger JP; Lemire P; Galbas T; Gottschalk M; Thibodeau J; Segura M
Front Immunol; 2018; 9():1199. PubMed ID: 29899744
[No Abstract] [Full Text] [Related]
10. Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing.
Simmons DP; Wearsch PA; Canaday DH; Meyerson HJ; Liu YC; Wang Y; Boom WH; Harding CV
J Immunol; 2012 Apr; 188(7):3116-26. PubMed ID: 22371391
[TBL] [Abstract][Full Text] [Related]
11. The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease.
Stüve O; Youssef S; Slavin AJ; King CL; Patarroyo JC; Hirschberg DL; Brickey WJ; Soos JM; Piskurich JF; Chapman HA; Zamvil SS
J Immunol; 2002 Dec; 169(12):6720-32. PubMed ID: 12471103
[TBL] [Abstract][Full Text] [Related]
12. Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effects.
Lee YS; Kim SH; Cho JA; Kim CW
Exp Mol Med; 2011 May; 43(5):281-90. PubMed ID: 21464590
[TBL] [Abstract][Full Text] [Related]
13. Repression of IFN-gamma induction of class II transactivator: a role for PRDM1/Blimp-1 in regulation of cytokine signaling.
Tooze RM; Stephenson S; Doody GM
J Immunol; 2006 Oct; 177(7):4584-93. PubMed ID: 16982896
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
Dolan BP; Gibbs KD; Ostrand-Rosenberg S
J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
[TBL] [Abstract][Full Text] [Related]
15. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
[TBL] [Abstract][Full Text] [Related]
16. The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and function.
Yang K; Neale G; Green DR; He W; Chi H
Nat Immunol; 2011 Jul; 12(9):888-97. PubMed ID: 21765414
[TBL] [Abstract][Full Text] [Related]
17. Adaptor protein-3 in dendritic cells facilitates phagosomal toll-like receptor signaling and antigen presentation to CD4(+) T cells.
Mantegazza AR; Guttentag SH; El-Benna J; Sasai M; Iwasaki A; Shen H; Laufer TM; Marks MS
Immunity; 2012 May; 36(5):782-94. PubMed ID: 22560444
[TBL] [Abstract][Full Text] [Related]
18. Adenosine signaling inhibits CIITA-mediated MHC class II transactivation in lung fibroblast cells.
Fang M; Xia J; Wu X; Kong H; Wang H; Xie W; Xu Y
Eur J Immunol; 2013 Aug; 43(8):2162-73. PubMed ID: 23681904
[TBL] [Abstract][Full Text] [Related]
19. IL-1 beta inhibits IFN-gamma-induced class II MHC expression by suppressing transcription of the class II transactivator gene.
Rohn W; Tang LP; Dong Y; Benveniste EN
J Immunol; 1999 Jan; 162(2):886-96. PubMed ID: 9916712
[TBL] [Abstract][Full Text] [Related]
20. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
Machy P; Serre K; Baillet M; Leserman L
J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
